{
  "id": 18194528,
  "title": "Nurix CFO Hans van Houte sells $74,562 in shares",
  "url": "https://urgent.news/2026/11/04/nurix-cfo-hans-van-houte-sells-74-562-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-04T22:31:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/nurix-cfo-hans-van-houte-sells-74562-in-shares-93CH-5001720"
  },
  "original_language": "en",
  "account": "Hans van Houte, Nurix Therapeutics' CFO, divested $74,562 worth of the company's stock on November 4, 2026, according to an SEC filing. The sales were made using a pre-approved trading plan, with shares sold at prices between $15.3824 and $16.2018. Two separate transactions accounted for the sale, one involving 3,300 shares at an average price of $15.3824 per share and the other 1,469 shares at a weighted average price of $16.2018 per share. Post-sale, van Houte still owns 42,745 shares of Nurix Therapeutics. The stock currently trades at $15.95, marking a 41% decrease over the past week. Despite this volatility, Nurix maintains a favorable financial health score and appears undervalued in InvestingPro's analysis. The company's recent quarterly report showcased strong results, including a net gain of $4.73 per share and $673.1 million in revenue from collaborations and licenses. This performance earned the biotech firm a higher price target from H.C. Wainwright and an increase from Stifel, both expressing optimism about the company's prospects. However, Nurix faces challenges, such as Sanofi discontinuing a Phase 1 trial of SAR448272, which may impact future earnings. Despite these setbacks, other analysts remain bullish, with Wells Fargo and Jefferies lowering their price targets but retaining a positive outlook.",
  "summary": null,
  "key_points": [
    "CFO Hans van Houte sold $74,562 worth of Nurix shares on November 4, 2026",
    "Two transactions divided the sale: 3,300 shares at $15.3824 and 1,469 at $16.2018",
    "Post-sale, van Houte retains 42,745 shares of Nurix Therapeutics"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}